GREENSBORO, N.C. — Biotech company ProKidney will no longer be coming to Greensboro, according to the City of Greensboro ...

The fate is uncertain for a proposed high-profile ProKidney Corp. manufacturing plant in Greensboro after the Winston-Salem ...

Headquartered in Winston-Salem, ProKidney leases an undetermined amount of space at the general-industrial-zoned building at ...

ProKidney, which works to treat chronic kidney disease, had previously announced plans to expand its operation into ...

It is unclear what will happen to ProKidney's plans for a $458-million, 330-job commercial manufacturing facility in ...

The NC Child-Commerce report estimated that with legislative and other public-private supports of several key child care and ...

Prokidney Corp. ( (PROK) ) has released its Q3 earnings. Here is a breakdown of the information Prokidney Corp. presented to its investors.

Judah Frommer, an analyst from Morgan Stanley, maintained the Hold rating on ProKidney (PROK – Research Report). The associated price target remains the same with $3.00. Judah Frommer has given his ...

FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencel; ...

ProKidney's REACT® therapy shows kidney function stabilization. Find out why PROK stock is risky due to cash issues and ...

The live webcasts will also be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Following the completion of each event, a replay ...